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Abstract
Background: Computerized alert and reminder systems have been widely accepted and applied to various patient
care settings, with increasing numbers of clinical laboratories communicating critical laboratory test values to
professionals via either manual notification or automated alerting systems/computerized reminders. Warfarin, an
oral anticoagulant, exhibits narrow therapeutic range between treatment response and adverse events. It requires
close monitoring of prothrombin time (PT)/international normalized ratio (INR) to ensure patient safety. This study
was aimed to evaluate clinical outcomes of patients on warfarin therapy following implementation of a Personal
Handy-phone System-based (PHS) alert system capable of generating and delivering text messages to
communicate critical PT/INR laboratory results to practitioners’ mobile phones in a large tertiary teaching hospital.
Methods: A retrospective analysis was performed comparing patient clinical outcomes and physician prescribing
behavior following conversion from a manual laboratory result alert system to an automated system. Clinical
outcomes and practitioner responses to both alert systems were compared. Complications to warfarin therapy,
warfarin utilization, and PT/INR results were evaluated for both systems, as well as clinician time to read alert
messages, time to warfarin therapy modification, and monitoring frequency.
Results: No significant differences were detected in major hemorrhage and thromboembolism, warfarin
prescribing patterns, PT/INR results, warfarin therapy modification, or monitoring frequency following
implementation of the PHS text alert system. In both study periods, approximately 80% of critical results led to
warfarin discontinuation or dose reduction. Senior physicians’ follow-up response time to critical results was
significantly decreased in the PHS alert study period (46.3% responded within 1 day) compared to the manual
notification study period (24.7%; P = 0.015). No difference in follow-up response time was detected for junior
physicians.
Conclusions: Implementation of an automated PHS-based text alert system did not adversely impact clinical or
safety outcomes of patients on warfarin therapy. Approximately 80% immediate recognition of text alerts was
achieved. The potential benefits of an automated PHS alert for senior physicians were demonstrated.
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Background
Computerized clinical decision support systems (CDSS)
are information technology systems designed to assist
health care providers in the clinical decision-making pro-
cess by providing treatment recommendations, medication
use reminders, and alert prompts [1-12]. Computerized
alert and reminder systems are typically linked to labora-
tory results within an electronic medical record system to
determine if alerts should be sent to the health care pro-
fessional [4,7,9,11,12]. These new technologies have been
widely accepted and applied to various patient care set-
tings [2,13], with increasing numbers of clinical labora-
tories communicating critical laboratory test values to
healthcare professionals via such alert systems.
The concept of the critical laboratory value, or so-
called “panic” value, was first proposed in 1972. Patients
may experience life-threatening events if care providers
remain unaware of abnormally high or low test results as
a result of untimely notification, consequently preventing
the implementation of urgent interventions [14]. A medi-
cal center demonstrated the association between the
volume of critical values per month and adverse events in
the following months [15]. Prompt reporting of critical
laboratory values has not only been a key patient safety
goal of the World Health Organization since 2004 [16],
but is also a key component of The Joint Commission
[17] and College of American Pathologists accreditation
standards [18].
In general, standard transmission modes for communi-
cating critical laboratory values include manual notifica-
tion and automated alerting systems/computerized
reminders. Various approaches of alerting health care pro-
viders of critical laboratory values have been described in
the literature and include manually contacting the ward or
provider by telephone, sending messages to physicians by
pager, utilizing short message service to providers’ mobile
phones, automated paging, placing written alerts in the
medical record, fax or email reporting, computer reminder
systems, and combining both written alerts plus verbal
clinical advice [13,19-26]. A recent meta-analysis revealed
that call centers which reported critical values via tele-
phone to prescribers successfully facilitated the timeliness
of critical reporting for inpatients. The evidence for auto-
mated notification systems, however, was insufficient in
showing significant benefits [13].
A computerized alert system was first advocated by
the Patient Safety Committee (PSC) of the Department
of Health, Taiwan, in 2003 to improve health care qual-
ity and patient safety and to reduce the risk of medica-
tion errors [27]. Twenty-one medical centers in Taiwan
developed High Risk Reminder (HRR) systems capable
of automatically delivering high-risk alerts to physicians
via Personal Handy-phone System (PHS) text messages
when laboratory or pathology results exceeded normal
ranges. Due to the lack of universal consensus on criti-
cal value parameters for triggering urgent communica-
tion to care providers, the operation and impact of these
systems may vary between institutions [23].
Warfarin is an oral anticoagulant indicated for the pro-
phylaxis and treatment of thromboembolic disorders. It is
well known for its narrow therapeutic range, and there-
fore, requires close monitoring of treatment response and
adverse events. The correlation between warfarin dose and
therapeutic effect is non-ideal, with considerable inter-
individual variation. Treatment guidelines and medical
consensus recommend routine measurement of prothrom-
bin time (PT) / international normalized ratio (INR). INR
is the standardized ratio of a patient’s PT value to the
mean PT of the normal population, and is utilized for war-
farin therapy monitoring due to the variability in thrombo-
plastin responsiveness of different PT testing reagents
[28,29]. Supratherapeutic PT/INR increases the risk of
hemorrhagic events, while subtherapeutic PT/INR
increases the risk of thromboembolic events [30-35].
Various physiologic and environmental factors such as
genetic predisposition (e.g., single nucleotide polymorph-
ism (SNP) of cytochrome P450 (CYP) 2C9 and vitamin K
oxide reductase complex 1 (VKORC1) enzymes), physical
condition (e.g., hepatic dysfunction), diet (e.g., vitamin
K rich foods, use of dietary supplements), and concomi-
tant drug therapy (e.g., antibiotics, antiplatelet therapy,
traditional Chinese medicine, and herbal medicine) are
known to influence the therapeutic effect of warfarin
[36-41]. Clinicians are thus required to routinely monitor
and maintain a therapeutic PT/INR to ensure patient
safety and treatment effectiveness [29].
Multiple goal INR ranges for warfarin treatment are
recommended in current practice guidelines and consen-
sus for different indications and patient populations
[28,29]. For individuals of Caucasian descent, a target
INR range of 2.0 to 3.0 is recommended for most treat-
ment indications while a target range of 2.5 to 3.5 is
recommended for patients with mechanical heart valve
replacements. Lower target INR ranges between 1.5 to
3.0 for the Asian population have been proposed, but
remain controversial [28,29,32,42-49]. Frequency of mon-
itoring PT/INR ranges from daily in patients newly
initiated on warfarin to up to 12 weeks in outpatients
with consistently stable PT/INR values [28].
Two early review articles summarized that warfarin
therapy resulted in major bleeding rate in an average of
1.7% to 3% of patients per year, and fatal bleeding in 0.6%
to 0.8% of patients per year [50,51]. Bleeding is closely
associated with the intensity of anticoagulation (INR > 5),
bleeding history (especially GI bleeding), advanced age,
presence of serious comorbid conditions such as cancer
and renal/hepatic insufficiency, alcohol abuse, and the
use of concomitant therapies, etc [29]. Strategies to
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reverse the effect of supratherapeutic INR include inter-
ruption of warfarin administration, dose reduction, and
vitamin K administration, etc. Blood derivatives, such as
fresh frozen plasma, prothrombin complex concentrates,
and recombinant activated factor VII can also be consid-
ered as rescue strategies for major bleeding [29].
Automated alert systems have been developed to
decrease clinician notification time of critical suprathera-
peutic INR results and to improve the time to initiate cor-
rective therapy. The impact of computerized reminder
systems on clinician performance and patient outcomes,
however, has not been well studied. Several studies have
suggested that treatment efficiency with the assistance of
paper- based methods is superior to computerized systems
[4-6]. In Garg et al’s. [1] analysis of the impact of compu-
terized diagnostic systems, reminder systems, disease man-
agement systems, and drug-dosing or prescribing systems
on practitioner performance and patient outcomes from
1998 through 2004, computerized systems were found to
improve practitioner performance but failed to signifi-
cantly improve patient outcomes. Key CDSS features asso-
ciated with improved practitioner performance included
the use of a graphical interface [3], automatic prompting
of the end user to utilize the system (versus requiring
users to actively self-initiate the system) [1], and CDSS
development by individuals with a medical background
and knowledge of institutional policies [1].
Prior to May 2007, the Department of Laboratory Medi-
cine at the National Taiwan University Hospital (NTUH)
manually communicated critical PT/INR results to
clinicians via telephone. In a number of Asian countries,
PHS-based mobile phone network systems operating
within the 1880-1930 MHz frequency band are commonly
utilized for hospital communications. An automated PHS
alert system reporting critical PT/INR results was thus
developed in an effort to promote the safer use and man-
agement of warfarin therapy.
All PT/INR results at NTUH are stored in a Department
of Laboratory Medicine database. If a PT/INR value
exceeds the threshold value (PT >50 seconds, approxi-
mately INR >4.0), the laboratory information management
system automatically creates a prompt to be reviewed by a
laboratory technician. Once a prompt is reviewed, the
technician sends a text message via the hospital reporting
system alerting the prescribing clinician and on-call emer-
gency department (ED) physician. Information delivered
in the alert includes the patient name, patient medical
identification (ID) number, and the critical PT/INR result
and date. Prescribers are encouraged to confirm message
delivery via the NTUH intranet.
This study was embarked upon to assess the impact of
the newly implemented automated PHS text alert system
on clinician prescribing behavior, specifically warfarin
dosing, monitoring frequency, and medication safety
(incidence of severe hemorrhage and thromboembolic
events), as well as to identify potential opportunities for
PHS alert system improvement.
Methods
Study settings
National Taiwan University Hospital (NTUH) is a 2,500
bed tertiary teaching hospital in Taipei, Taiwan, and dis-
penses approximately 20,000 outpatient prescriptions
daily. Prior to the implementation of the PHS text alert
system in May 2007, laboratory personnel manually noti-
fied clinicians verbally of PT results >50 seconds
(approximately INR > 4.0). The newly implemented PHS
alert system possesses functionality to automatically gen-
erate and send text messages to clinicians 24 hours a day,
7 days a week.
Study participants
Patients with warfarin therapy managed by the hospital’s
outpatient clinics and had received at least one warfarin
prescription between January 1, 2006 and December 31,
2008 were included in the study. Patient data collected
from the hospital electronic medical record and prescrip-
tion database included: warfarin dose and amount dis-
pensed, PT/INR results, ED visits, hospital admissions,
vitamin K administration, procedure records, patient med-
ical record number, sex, birthdate, current medications
including prescribing date, dose, treatment duration, num-
ber of refills and refill status, prescriber department, and
ICD-9-CM codes for major and minor diagnoses [52].
Data collected pertaining to PT/INR results included
patient medical ID number, prescribers’ department, ward
number if hospitalized, and PT/INR results and dates.
Data collected pertaining to ED visits included patient
medical ID number, visit date, and ICD-9-CM codes for
major and minor diagnoses. Data collected pertaining to
hospital admissions included patient medical ID number,
admission date, discharge date, and ICD-9-CM codes for
major and minor diagnoses. Data collected pertaining to
procedure records included patient medical record num-
ber and the types and dates of procedures performed.
Evaluation of the automated PHS text alert system
PT/INR results exceeding a threshold value of 50 seconds
were considered critical results requiring immediate
follow-up, with a PHS alert subsequently sent to notify the
appropriate physicians. Warfarin regimen modification
practices prior to and following implementation of the
PHS alert system were also assessed. The study initially
utilized one-year data (May 2006 to May 2007 and
September 2007 to September 2008), but seasonal varia-
tions were recognized to potentially affect the incidence of
warfarin-related adverse events. To account for these sea-
sonal variations, the study periods were extended, and
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defined January 1, 2006 through May 16, 2007 (16.5
months) as the manual alert system study period, and
September 1, 2007 through December 31, 2008 (16 months)
as the PHS alert system study period. A transition period
from May 17, 2007 through August 31, 2007 was excluded
from analysis. All physicians are equipped with hospital
released PHS phones and are required to check regularly
PHS alerts in their phone.
Basic patient demographics (age, gender, underlying dis-
ease, etc.), treatment duration, treatment indication, daily
warfarin dose, PT/INR results, and PT/INR monitoring fre-
quency were analyzed. The incidence of warfarin-associated
adverse events of major thromboembolism and major
hemorrhage requiring ED visits and/or hospital admission
were analyzed for both the manual alert and PHS alert
study periods. Physician follow-up actions following receipt
of critical PT/INR alert messages, such as warfarin dose
adjustments, time to next PT/INR test, and vitamin K use
were analyzed. Warfarin dosing intervals exceeding 30 days
were defined as treatment interruption. Lastly, the influence
of physician seniority on warfarin therapy modification
practices was assessed, as age is known to play an impor-
tant role in the evaluation of computerized systems impact
on end-user behavior. Senior physicians were defined
according to Department of Health (Executive Yuan,
Taiwan, ROC) guidelines as attending physicians over the
age of 50 or physicians practicing for more than 15 years
[27]. Physicians not meeting this definition were defined as
junior physicians.
Results
Change in demographic profiles
Patient demographics comparing age, underlying disease,
and indications for warfarin therapy are summarized in
Table 1. A total of 3,497 patients were included in the
manual alert study period and a total of 3,781 patients
were included in the PHS alert group. For both study peri-
ods, there were slightly more male patients than female
patients. The average patient age was 59 years of age, with
a median age of 63 and 61 years of age for the manual
alert and PHS alert groups, respectively. Treatment indica-
tions identified included atrial flutter/fibrillation, arterial
embolism/deep vein thrombosis, cerebral vascular disease,
coronary artery disease, heart failure, coagulation factor
abnormality, pulmonary embolism, and other cardiovascu-
lar diseases. The most common underlying comorbid dis-
ease states identified were hypertension (26% vs. 28%),
diabetes mellitus (16% vs. 15%), and malignancy (7% in
both groups).
There was no significant difference in age by the
Student’s t-test (P = 0.124) or age over a 10-year interval
(P = 0.700). Similarly, no significant differences in gender
(P = 0.828), underlying disease states (P = 0.113), or
treatment indication (P = 0.744) by the Chi-square test
between the two study periods were found.
Change in warfarin dosing and PT/INR
Over the three-year study period, the average daily war-
farin dose was approximately 3 mg, with the majority of
patients prescribed a daily dose between 2 to 2.5 mg.
No significant difference in the mean daily warfarin
dose between the two study groups was found by the
Student’s t-test (p = 0.503). Although slightly more
patients that received daily doses of 5.0 to 5.5 mg were
in the PHS alert group, the daily dose distribution dif-
ference between both study groups were statistically
insignificant.
Table 2 summarizes PT/INR measurements from out-
patient clinic, inpatient, and ED records included for
analysis from both study periods. PT/INR results
obtained one day prior to any surgery were excluded
Table 1 Patient Demographics
Manual Alerts PHS Alerts P
Demographics
Patients, n 3497 3781
Duration (days) 501 488
Patient-years 2,883 3,367
Male (%) 1,885 (53) 1,996 (52.8) 0.83
Age
Mean ± SD 59.6 ± 17.8 59.0 ± 18.0 0.12
< 20 125 (3.6%) 156 (4.1%) 0.7
20-29 99 (2.8%) 110 (2.9%)
30-39 203 (5.8%) 234 (6.2%)
40-49 456 (13.0%) 471 (12.5%)
50-59 687 (19.6%) 784 (20.7%)
60-69 784 (22.4%) 843 (22.3%)
71-80 759 (21.7%) 779 (20.6%)
>80 384 (11.0) 404 (10.7%)
Underlying Diseases Case (%) Case (%) 0.11
Hypertension 920 (26) 1,047 (28)
Diabetes mellitus 556 (16) 571 (15)
Malignancy 248 (7) 279 (7)
Treatment Indications Case (%) Case (%) 0.74
Atrial flutter/atrial
fibrillation
950 (27) 1,102 (29)
Arterial embolism/deep
venous thrombosis
626 (18) 667 (18)
Cerebral vascular disease 493 (14) 529 (14)
Coronary artery disease 429 (12) 502 (13)
Heart failure 425 (12) 455 (12)
Coagulation factor
abnormality
236 (7) 255 (7)
Other cardiovascular
diseases
202 (6) 248 (7)
Pulmonary embolism 39 (1) 52 (1)
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from analysis due to the common practice of holding
anticoagulation treatment to prevent excessive hemor-
rhaging during surgical procedures. The difference
between mean INR values of 2.02 ± 1.38 in the manual
alert group and 2.00 ±1.28 in the PHS alert group were
insignificant by Mann-Whitney U test (P = 0.384) with
similar INR distribution between the two groups. The
majority of PT/INR values ranged between 1.0 to 1.5
(about 33%) and 1.5 to 2.0 (26%). There was no signifi-
cant difference in PT/INR measurement frequency by
Fisher’s exact test (P = 0.369) between the two groups.
Comparison of thromboembolism and major hemorrhage
The incidence of major thromboembolism and hemorrhage
before and after implementation of the PHS alert system
was compared in Table 3. In general, fewer critical PT/INR
results occurred during the PHS alert study period com-
pared to the manual alert study period despite the higher
volume of PT/INR tests ordered in the outpatient depart-
ments during the PHS alert study period. The incidence of
major thromboembolic events was 1.6% for both groups
(P = 0.709). The rate of hemorrhagic events was 3.1% and
4.2% in the manual alert and PHS alert study periods,
respectively, but no significant difference was found between
the two study periods by the Chi-square test (P = 0.198).
Clinician response to alerts
The impact of the automated PHS alert system implemen-
tation on warfarin prescribing practices was analyzed by
investigating a) the frequency of warfarin dose reduction
or holding warfarin, b) change in clinician follow-up
PT/INR ordering time, and c) incidence of vitamin K
administration within 7 days of a critical PT/INR result. In
the manual alert study group, 583 (3.7%) of 15,790 cases
experienced critical PT values. Among these individuals,
349 (59.9%) of the 583 patients’ warfarin therapy was con-
tinued, of which 230 (65.9%) of the 349 patients received a
reduced warfarin dose. Sixteen (7.0%) of 230 warfarin pre-
scriptions were written on the same day of a critical
PT/INR result, with the remaining prescriptions written
on the days following the reported critical PT/INR result.
The average (±s.d.) time between a reported critical PT
result and warfarin dose reduction (lag period) in the man-
ual alert study period was 11.13 ± 7.65 days. During the
PHS alert study period, 444 critical results (2.7%) were
reported out of 16,704 PT/INR tests. Among the critical
results for the PHS alert group, 271 (61.0%) of 444 cases
resulted in continuation of warfarin therapy, of which 186
(68.6%) of 271 cases resulted in warfarin dose reduction.
Twenty (10.8%) of 186 warfarin prescriptions were written
the same day a critical PT/INR result was reported, with the
remainder written on the days following the reported criti-
cal PT/INR. The average lag period in the PHS alert study
period was 11.32 ± 8.17 days. In summary, approximately
79.6% (464 cases) of the critical PT/INR values during the
manual alert study period were managed by discontinuing
warfarin or reducing the warfarin dose, compared to 80.9%
(359 cases) in the PHS alert study period. There was no sig-
nificant difference between the two groups in the number
of prescriptions written for a reduced warfarin dose (P =
0.45) or the lag period (P = 0.814) by the Chi-square test.
The time to follow-up PT/INR following receipt of a
critical PT/INR alert did not differ significantly between
the two study periods by the Chi-square test (P = 0.298).
For both study periods, approximately a third of prescri-
bers repeated PT/INR testing within 1 day. More than a
third of prescribers in both study groups did not order a
repeat PT/INR until 1 week later, and in some cases, not
until 1 month following the initial critical result.
In the manual alert group, 11 (1.9%) of 583 cases uti-
lized vitamin K to reverse a supratherapeutic PT/INR
within 7 days of the critical PT/INR result, while 12
(2.7%) of 444 cases in the PHS alert group utilized vita-
min K. No statistically significant difference in vitamin
K administration was detected between the two groups
by the Chi-square test (P = 0.35).
Clinician performance by department
Clinician continuation of warfarin therapy and the rate of
dose reduction following notification of a critical PT/INR
Table 2 PT/INR Measurements
Manual Alerts PHS Alerts P value
Patients, n 3,497 3,781




N = 30,981 N = 32,297 0.384+
Mean ± SD 2.02 ± 1.38 2.00 ± 1.28
Median 1.72 1.70
Number (%) Number (%) 0.369#
INR < 1.0 1,172 (4) 1,570 (5)
1.0-1.4 10,242 (33) 10,809 (33)
1.5-1.9 8,137 (26) 8,320 (26)
2.0-2.4 5,069 (16) 5,154 (16)
2.5-2.9 2,734 (9) 2,776 (9)
3.0-3.4 1,397 (5) 1,425 (4)
3.5-3.9 717 (2) 751 (2)
4.0-4.4 417 (1) 428 (1)
4.5-4.9 269 (1) 260 (1)
5.0-5.4 198 (1) 182 (1)
5.5-5.9 124 (<1) 127 (<1)
6.0-6.5 74 (<1) 80 (<1)
6.5-6.9 61 (<1) 58 (<1)
7.0-7.4 50 (<1) 45 (<1)
7.5-8.9 41 (<1) 41 (<1)
> 8.0 279 (1) 271 (1)
* Including outpatient, inpatient, and ED laboratory results; +Using Mann-
Whitney U test; #using Fisher’s exact test
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result were compared between the two study periods in
the medicine and surgery departments due to prescribing
behaviors unique to each department.
The rate of warfarin dose reduction did not signifi-
cantly differ between the two study periods in either the
medicine (P = 0.935) or surgery departments (P =
0.829). During the manual alert study period, 146 criti-
cal PT/INR results were reported in the medicine
department. In 114 (78.1%) of these 146 cases, warfarin
therapy was continued, with 84 (73.7%) of the 114 cases
resulting in dose reduction in an average (±s.d.) lag per-
iod of 8.9 ± 6.2 days. During the PHS alert study period,
117 critical PT/INR results occurred. Eighty-five (72.6%)
of these 117 cases resulted in continued warfarin therapy,
of which 62 (72.9%) of the 85 cases resulted in dose reduc-
tion in an average (±s.d.) lag period of 8.6 ± 8.4 days.
There was no significant difference in the medicine depart-
ment between the two groups in the number of prescrip-
tions written reflecting a reduced warfarin dose (P = 0.935)
or in the lag period (P = 0.803) by the Chi-square test.
During the manual alert study period, 130 critical PT/
INR results were reported in the surgery department. In
100 (76.9%) of these cases, warfarin therapy was contin-
ued, of which 65 (65%) of the 100 cases lead to dose
reduction in an average (±s.d.) lag period of 8.0 ± 8.0 days.
During the PHS alert study period, 87 critical PT/INR
values were reported. Fifty-three (60.9%) of the 87 critical
values resulted in continued warfarin therapy with 33
(62.3%) of these 53 cases resulting in dose reduction in an
average (±s.d.) lag period of 8.2 ± 8.4 days. Similar to the
medicine department, no significant difference in the
number of prescriptions written reflecting dose reduction
(P = 0.829) or in the lag period (P = 0.884) was observed
between the two study periods by the Chi-square test.
Although the warfarin discontinuation rate was higher in
the PHS alert study period for both departments, no sig-
nificant difference in the discontinuation rate between the
two study periods was seen.
The distribution in time intervals between repeat PT/INR
testing and the initial critical PT/INR result did not
significantly differ between the two study periods in
the medicine (P = 0.406) or surgery (P = 0.874) depart-
ments by the Chi-square test. For both study periods,
more than 60% of prescribers did not order a repeat
PT/INR until 8 or more days after the initial critical
PT/INR result.
Clinical practice by physician seniority
The rate of warfarin dose reduction following a critical
PT/INR result did not significantly differ between the
two study periods for either senior physicians (P = 0.632)
or junior physicians (P = 0.946). Similarly, the rate of
continuing warfarin therapy following the reporting of a
critical PT/INR result (P = 0.97) did not differ between
senior and junior physicians.
The follow-up response time to critical PT/INR results
for senior physicians, however, was significantly different
between the two study periods (P = 0.015), but not for
junior physicians (P = 0.102). More senior physicians
repeated PT/INR tests within 1 day in the PHS alert
study period compared to the manual alert study period,
suggesting the automated PHS alert system aided senior
physicians in decreasing the follow-up response time to
critical PT/INR results (Table 4, Table 5).
Discussion
Clinical impact of transitioning to an automated PHS
alert system
Patient demographics and warfarin prescribing patterns
remained unchanged between the manual alert and PHS
alert study periods. Transitioning from a manual alert sys-
tem to an automated PHS alert system also did not lead to
increased incidences of major thromboembolism and
hemorrhage when comparing records over a period of 1.5
years. Although a higher number of critical PT/INR results
occurred in the manual alert group compared to the PHS
group, there was no significant difference in the incidence
of warfarin-associated complications between the two
groups. Concerns, however, were raised regarding the ease
of deleting text alerts by prescribers, but immediate
Table 3 Major Hemorrhage and Thromboembolism Complications
Manual Alerts PHS Alerts P value
Patients, n 3497 3781
PT/INR measurements+ 15,790 16,704
PT value > 50, n (%) 583 (4) 444 (3) < 0.01
Number of complications, event (person) 164 (139) 223 (171) 0.24*
Number of thromboembolic events, event (person) 56 (50) 62 (58) 0.709*
Number of hemorrhagic events, event (person) 108 (96) 161 (123) 0.198*
Major hemorrhage, event (person) 94 (86) 131 (111)
Treatment with vitamin K, event (person) 14 (12) 30 (18)
* P values calculated by comparing percentage of patients with complications in both study groups
+ Only outpatients included
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recognition and response rates by physicians of approxi-
mately 80% were achieved.
Physician behavior was measured by analyzing the rate of
warfarin dose reduction, time to repeat PT/INR order, and
vitamin K administration. In general, clinician behavior
was not affected by the implementation of the new alert
system. Additionally, implementation did not significantly
impact physician behavior by medical department. Surpris-
ingly, transitioning to the automated PHS alert system
resulted in increased monitoring frequency and shortened
time to repeat PT/INR testing by senior physicians, and
could be explained by 1) fatigue to manual phone call alerts
and resulting job interruption, 2) use of PHS text alerts as
self-reminders for follow-up, or 3) increased administrative
and inter-department meeting responsibilities of senior
physicians compared to junior physicians. Our results
demonstrated that implementation of an automated alert
system did not adversely affect patient outcomes or
clinician performance, but instead positively impacted
senior physicians by decreasing follow-up response times
to critical PT/INR results.
Evaluation of the implementation of the PHS text alert
system
Prior studies have suggested computerized systems
improve medical efficiency, while other studies have sug-
gested computerized systems require increased user time
and effort compared to manual or paper-based systems.
Barriers to implementing an optimal computerized system
include incorrect use and incompatibility with a provider’s
existing workflow. As such, important factors contributing
to successful computerized systems include good work-
flow integration, user acceptance, interoperability with
existing infrastructure, and upgradability [1]. The benefits
of utilizing computerized alert systems in health manage-
ment systems to avoid illegible handwriting, poor commu-
nication, and inadvertent disregard of pertinent medical
information have been recognized, but excessive alerts
may result in user alert fatigue and thereby decrease qual-
ity of care [1].
Workflow suitability or laboratory personnel accep-
tance of the PHS alert system was not surveyed in the
present study. Based on the results, however, a PHS
alert system possessed advantages of maintaining the
existing quality of care, patient outcomes, and clinician
performance while simultaneously reducing resources
and time consumed to manually communicate critical
laboratory results to providers. An additional advantage
of PHS alert systems is the ability to alert clinicians in a
manner less disruptive to their workflow, especially for
individuals with increased administrative and clinical
responsibilities. Conversely, manual telephone call alerts
are likely to cause increased workflow disruption com-
pared to text alerts, potentially leading to poor commu-
nication and increasing the risk of patient adverse
events. Anecdotally, several of our physicians reported
PHS text alerts served well as personal follow-up remin-
ders, whereas they were previously less able to recall all
details of critical alerts delivered by manual phone mes-
sages. One disadvantage of the PHS alert system, how-
ever, is the unavailability of PHS phones for adjunct
physician staff. As such, adjunct physicians are unable
to receive critical alerts sent via the PHS alert system.
Areas for potential improvement to the PHS alert system
Currently recommended INR goal ranges for warfarin
treatment in Western countries range from 2.0 to 3.5,
with the literature suggesting hemorrhage risk dramati-
cally increasing when INR exceeds 5.0 [49,50]. Several
studies, however, have suggested a lower target INR
range of 1.5 to 2.5 for the Asian population to decrease
the rate of hemorrhagic events [32,42-50]. As the
NTUH laboratory currently utilizes one template for
text messages sent for any critical PT/INR result, a
potential area for future system improvement is tiering
alert message content by pre-specified PT/INR result
ranges to assist clinicians in better distinguishing the
risk of warfarin-associated complications. Examples
include displaying additional clinical information perti-
nent to increased bleeding risk when PT exceeds 100
seconds or information pertinent to increased throm-
boembolic risk for results at lower than goal ranges.
Genetic polymorphisms of CYP2C9 and VKORC1 are
major genetic determinants of the pharmacokinetics and
Table 4 Time to Repeat PT/INR Ordered by Senior
Physicians
Manual Alerts PHS Alerts P value
Interval to next PT/INR (days) Number (%) Number (%) 0.015
0-1 64 (24.7) 45 (36.3)
2-3 38 (14.7) 8 (6.5)
4-7 32 (12.4) 9 (7.3)
8-30 64 (24.7) 30 (24.2)
> 30 51 (19.7) 17 (13.7)
N/A 10 (3.9) 15 (12.1)
Table 5 Time to Repeat PT/INR Ordered by Junior
Physicians
Manual Alerts PHS Alerts P value
Interval to next PT/INR (days) Number (%) Number (%) 0.102
0-1 103 (33.3) 97 (31.4)
2-3 37 (12.0) 35 (11.3)
4-7 27 (8.7) 34 (11.0)
8-30 63 (20.4) 78 (25.2)
> 30 62 (20.1) 39 (12.6)
N/A 17 (5.5) 26 (8.4)
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pharmacodynamics of warfarin. S-warfarin, the more
potent enantiomer of warfarin, is mainly metabolized via
oxidation by CYP2C9. Variant SNPs of CYP2C9, such as
2C9*2 and 2C9*3, have been associated with significant
decreases in S-warfarin metabolism, and have been asso-
ciated with elevated bleeding risk. Warfarin exerts its
therapeutic effect by inhibiting hepatic VKORC1, which
is involved in clotting factor synthesis. Individuals with
the VKORC1 1639G>A allele tend to produce less
VKORC1, and thus tend to require a lower warfarin dose
to achieve a therapeutic effect [52]. As such, studies
which have found up to a 40% variation in warfarin dose
could be explained by the influence of variant CYP2C9
and VKORC1 SNPs in the respective study populations
[53,54]. Due to a paucity of evidence demonstrating
improved clinical outcomes with the incorporation of
genotype information, the routine use of CYP2C9 and
VKORC1 genotyping for warfarin dosing has not been
recommended in current clinical practice guidelines [55].
Despite the lack of clinical evidence supporting geno-
type-guided dosing of warfarin, dosing recommendations
with consideration of different SNPs of CYP2C9 and
VKORC1 have been incorporated into the prescribing
information/package insert for warfarin [56]. When war-
farin is first prescribed, CDSS are capable of integrating
patient pharmacogenetic information with dosing recom-
mendations should genetic tests be available in the
respective institution, further increasing the usefulness of
a PHS alert system for follow-up monitoring of PT/INR.
Limitations
All assessments of this implementation process were
performed utilizing medical record databases specific to
our institution. Medical records from outside hospitals,
records documenting over-the- counter and alternative
medicine use, or patient self-maintained records were
unavailable. Moreover, our databases contained only
written medical records, and as such, any undocumen-
ted verbal communication or orders provided by clini-
cians to patients regarding warfarin dose adjustment or
held doses were unavailable. The nature of this retro-
spective study restricted us from observing potential
confounders in the physicians’ response and decision
making if those were not recorded in the database.
Additionally, patients experiencing major hemorrhagic
or thromboembolic events may have sought and
received treatment at outside institutions, leading to
potential underestimation of the incidence of major war-
farin-associated adverse events.
Conclusions
Implementation of an automated PHS alert system in place
of a manual verbal alert system did not compromise
patient outcomes or clinician performance. A major benefit
realized from the implementation of a PHS-based text alert
system was improvement in the quality of care provided by
senior physicians.
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